Sales of injectable anti-HIV therapeutics will reach $2 billion in 2029: GlobalData EP News Bureau Feb 27, 2021 Cabotegravir-based therapies are projected to generate 79 per cent of the sales of injectable therapeutics in the HIV market in…
US FDA approves ViiV Healthcare’s Cabenuva as complete long-acting regimen for HIV treatment EP News Bureau Jan 22, 2021 Cabenuva allows virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or…
